Looks like you’re on the US site. Choose another location to see content specific to your location
GSK Secures Second FDA Lung Cancer Approval from Nuvalent
GSK has secured its second US lung cancer approval from the $10.6bn Nuvalent acquisition. The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer previously treated with ALK inhibitors. Announced on 18 November 2026, the clearance lands four months after deal close and moves GSK from zero US lung cancer approvals to two inside a single calendar year.
Nelkarmi targets ALK-positive NSCLC and is designed to cover resistance mutations, cross the blood-brain barrier and offer high target selectivity. In the Phase I/II ALKOVE-1 trial, 49 per cent of previously treated patients achieved a confirmed overall response, with 52 per cent of responses lasting at least a year. GlobalData forecasts $1.2bn in Nelkarmi sales by 2032, alongside $830m for Jideytro (zidesamtinib), the ROS1-targeted asset approved a week after deal close. Tony Wood, chief scientific officer at GSK, noted “ALK-positive patients are often younger and can remain on treatment for years.”
Before 2026, GSK had never received a US approval for a lung cancer medicine. It now has two, both from Nuvalent, acquired for $10.6bn in July. For M&A analysts, this is an acquisition thesis validated against an unusually tight timeline. The current approval sits in the resistance setting, with the Phase III ALKAZAR study in TKI-naïve patients the path into first-line treatment. Citi analysts cite first-line entry as the key value driver; a positive readout would push the $1.2bn 2032 forecast upward and widen the TAM materially.
The commercial signal is a precision oncology M&A thesis validated inside four months, with Nelkarmi’s trajectory now hinging on the ALKAZAR first-line readout. Launch execution across two US precision oncology brands and the first-line expansion path remain critical near-term milestones. Expect the next 18 months to be defined by commercial scale-up rather than further NSCLC deal activity, with lung cancer anchoring GSK’s US oncology business.
For the latest updates and in-depth insights into the world of Pharmaceutical, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard